tiprankstipranks
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
US Market
VRDN
Viridian Therapeutics
RESEARCH TOOLSreports

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

1,473 Followers
See the Price Targets and Ratings of:

VRDN Analyst Ratings

Strong Buy
14Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Viridian
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$36.17
▲(91.97% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $36.17 with a high forecast of $50.00 and a low forecast of $20.00. The average price target represents a 91.97% change from the last price of $18.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","21":"$21","31":"$31","41":"$41","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.166666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$36.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21,31,41,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.15,21.52307692307692,23.896153846153844,26.269230769230766,28.64230769230769,31.015384615384612,33.38846153846154,35.761538461538464,38.13461538461539,40.50769230769231,42.88076923076923,45.253846153846155,47.62692307692308,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.15,20.45897435897436,21.767948717948716,23.076923076923077,24.385897435897434,25.694871794871794,27.003846153846155,28.31282051282051,29.62179487179487,30.93076923076923,32.23974358974359,33.54871794871795,34.857692307692304,{"y":36.166666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.15,19.215384615384615,19.28076923076923,19.346153846153847,19.41153846153846,19.476923076923075,19.54230769230769,19.607692307692307,19.673076923076923,19.73846153846154,19.803846153846152,19.869230769230768,19.934615384615384,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$36.17Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on VRDN
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$50→$46
Buy
144.16%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Viridian Therapeutics (NASDAQ: VRDN)
H.C. Wainwright Analyst forecast on VRDN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$22
Buy
16.77%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Bristol-Myers Squibb (NYSE: BMY)
Truist Financial Analyst forecast on VRDN
Gregory Renza
Truist Financial
Truist Financial
$18.84→$40
Buy
112.31%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), IDEAYA Biosciences (NASDAQ: IDYA) and Viridian Therapeutics (NASDAQ: VRDN)
Stifel Nicolaus Analyst forecast on VRDN
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$27.39→$48
Buy
154.78%
Upside
Reiterated
04/04/26
Stifel Nicolaus Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
Needham Analyst forecast on VRDN
Serge Belanger
Needham
Needham
$32
Buy
69.85%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Viridian Therapeutics (NASDAQ: VRDN)
William Blair Analyst forecast on VRDN
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
04/02/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Nuo Therapeutics (AURX)
Evercore ISI Analyst forecast on VRDN
Maneka Mirchandaney
Evercore ISI
Evercore ISI
$32
Buy
69.85%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR), Alto Neuroscience, Inc. (NYSE: ANRO) and Viridian Therapeutics (NASDAQ: VRDN)
Wells Fargo Analyst forecast on VRDN
Derek Archila
Wells Fargo
Wells Fargo
$29→$20
Hold
6.16%
Upside
Reiterated
03/31/26
Viridian Therapeutics price target lowered to $20 from $29 at Wells FargoViridian Therapeutics price target lowered to $20 from $29 at Wells Fargo
Wedbush Analyst forecast on VRDN
Laura Chico
Wedbush
Wedbush
$44→$37
Buy
96.39%
Upside
Reiterated
03/31/26
Viridian Therapeutics price target lowered to $37 from $44 at WedbushViridian Therapeutics price target lowered to $37 from $44 at Wedbush
Jefferies Analyst forecast on VRDN
Faisal Khurshid
Jefferies
Jefferies
$45→$29
Buy
53.93%
Upside
Assigned
03/30/26
Viridian Therapeutics price target lowered to $29 from $45 at JefferiesViridian Therapeutics price target lowered to $29 from $45 at Jefferies
Goldman Sachs Analyst forecast on VRDN
Richard Law CFA
Goldman Sachs
Goldman Sachs
$41→$36
Buy
91.08%
Upside
Reiterated
03/30/26
Viridian Therapeutics price target lowered to $36 from $41 at Goldman SachsViridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs
RBC Capital Analyst forecast on VRDN
Lisa Walter
RBC Capital
RBC Capital
$45→$42
Buy
122.93%
Upside
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX), DENTSPLY SIRONA (NASDAQ: XRAY) and Viridian Therapeutics (NASDAQ: VRDN)
TD Cowen Analyst forecast on VRDN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/26/26
Analysts' Top Healthcare Picks: Heron Therapeutics (HRTX), Viridian Therapeutics (VRDN)
UBS Analyst forecast on VRDN
Michael Yee
UBS
UBS
$50
Buy
165.39%
Upside
Initiated
01/07/26
Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS
Oppenheimer Analyst forecast on VRDN
Leland Gershell
Oppenheimer
Oppenheimer
$36
Buy
91.08%
Upside
Reiterated
11/06/25
Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on VRDN
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$50→$46
Buy
144.16%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Viridian Therapeutics (NASDAQ: VRDN)
H.C. Wainwright Analyst forecast on VRDN
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$22
Buy
16.77%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN) and Bristol-Myers Squibb (NYSE: BMY)
Truist Financial Analyst forecast on VRDN
Gregory Renza
Truist Financial
Truist Financial
$18.84→$40
Buy
112.31%
Upside
Reiterated
04/06/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), IDEAYA Biosciences (NASDAQ: IDYA) and Viridian Therapeutics (NASDAQ: VRDN)
Stifel Nicolaus Analyst forecast on VRDN
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$27.39→$48
Buy
154.78%
Upside
Reiterated
04/04/26
Stifel Nicolaus Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)
Needham Analyst forecast on VRDN
Serge Belanger
Needham
Needham
$32
Buy
69.85%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Viridian Therapeutics (NASDAQ: VRDN)
William Blair Analyst forecast on VRDN
Lachlan Hanbury Brown
William Blair
William Blair
―
Buy
―
Reiterated
04/02/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Nuo Therapeutics (AURX)
Evercore ISI Analyst forecast on VRDN
Maneka Mirchandaney
Evercore ISI
Evercore ISI
$32
Buy
69.85%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR), Alto Neuroscience, Inc. (NYSE: ANRO) and Viridian Therapeutics (NASDAQ: VRDN)
Wells Fargo Analyst forecast on VRDN
Derek Archila
Wells Fargo
Wells Fargo
$29→$20
Hold
6.16%
Upside
Reiterated
03/31/26
Viridian Therapeutics price target lowered to $20 from $29 at Wells FargoViridian Therapeutics price target lowered to $20 from $29 at Wells Fargo
Wedbush Analyst forecast on VRDN
Laura Chico
Wedbush
Wedbush
$44→$37
Buy
96.39%
Upside
Reiterated
03/31/26
Viridian Therapeutics price target lowered to $37 from $44 at WedbushViridian Therapeutics price target lowered to $37 from $44 at Wedbush
Jefferies Analyst forecast on VRDN
Faisal Khurshid
Jefferies
Jefferies
$45→$29
Buy
53.93%
Upside
Assigned
03/30/26
Viridian Therapeutics price target lowered to $29 from $45 at JefferiesViridian Therapeutics price target lowered to $29 from $45 at Jefferies
Goldman Sachs Analyst forecast on VRDN
Richard Law CFA
Goldman Sachs
Goldman Sachs
$41→$36
Buy
91.08%
Upside
Reiterated
03/30/26
Viridian Therapeutics price target lowered to $36 from $41 at Goldman SachsViridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs
RBC Capital Analyst forecast on VRDN
Lisa Walter
RBC Capital
RBC Capital
$45→$42
Buy
122.93%
Upside
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX), DENTSPLY SIRONA (NASDAQ: XRAY) and Viridian Therapeutics (NASDAQ: VRDN)
TD Cowen Analyst forecast on VRDN
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/26/26
Analysts' Top Healthcare Picks: Heron Therapeutics (HRTX), Viridian Therapeutics (VRDN)
UBS Analyst forecast on VRDN
Michael Yee
UBS
UBS
$50
Buy
165.39%
Upside
Initiated
01/07/26
Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS
Oppenheimer Analyst forecast on VRDN
Leland Gershell
Oppenheimer
Oppenheimer
$36
Buy
91.08%
Upside
Reiterated
11/06/25
Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

3 Months
xxx
Success Rate
13/24 ratings generated profit
54%
Average Return
+6.07%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 54.17% of your transactions generating a profit, with an average return of +6.07% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
13/21 ratings generated profit
62%
Average Return
+24.08%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +24.08% per trade.
2 Years
xxx
Success Rate
24/30 ratings generated profit
80%
Average Return
+40.04%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +40.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
11
7
6
13
16
Buy
26
28
30
20
14
Hold
0
0
1
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
37
35
37
36
33
In the current month, VRDN has received 30 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is 36.17.
Each month's total comprises the sum of three months' worth of ratings.

VRDN Financial Forecast

VRDN Earnings Forecast

Next quarter’s earnings estimate for VRDN is -$1.06 with a range of -$1.25 to -$0.94. The previous quarter’s EPS was -$1.08. VRDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.
Next quarter’s earnings estimate for VRDN is -$1.06 with a range of -$1.25 to -$0.94. The previous quarter’s EPS was -$1.08. VRDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.

VRDN Sales Forecast

Next quarter’s sales forecast for VRDN is $19.00K with a range of $0.00 to $133.00K. The previous quarter’s sales results were $132.00K. VRDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.
Next quarter’s sales forecast for VRDN is $19.00K with a range of $0.00 to $133.00K. The previous quarter’s sales results were $132.00K. VRDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 36.17.
    What is VRDN’s upside potential, based on the analysts’ average price target?
    Viridian Therapeutics has 91.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VRDN a Buy, Sell or Hold?
          Viridian Therapeutics has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Viridian Therapeutics’s price target?
            The average price target for Viridian Therapeutics is 36.17. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $20.00. The average price target represents 91.97% Increase from the current price of $18.84.
              What do analysts say about Viridian Therapeutics?
              Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of VRDN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.